Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
A health ministry panel on counterfeit drugs generally approved a draft final report on December 20, wrapping up its discussions on ways to ensure the reliability of Japan’s drug distribution system and thwart the entry of fake pills into the…
To read the full story
Related Article
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- MHLW to Discuss Drug Wholesalers’ License Requirements Related to Their “Operational Systems”
October 23, 2017
- MHLW to Discuss Redefinition of Drug “Seals”, Will Revise List of Examples of Seals Included in 1961 Notification
October 23, 2017
- Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
- With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
- MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
June 12, 2017
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…